Ernexa Therapeutics Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 19, 2020 and accepted by EDGAR at Mar 19, 2020, 16:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2019-01-01 to 2019-12-31 | $19.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $26.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $13.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $27.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$0.72 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | $2.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $128.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $3.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $6.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $14.1m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $6.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $9.0m | us-gaap:Liabilities |
| Current portion of debt | At period end2019-12-31 | $2.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2019-12-31 | $5.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-20-004343. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.